Introduction
In recent years, an increasing number of pharmacists in the United States are involved in such activities as clinical pharmacy services, pharmaceutical care, and collaborative drug therapy management. All of these activities will enhance the status of the pharmacy profession. Among them, collaborative drug therapy management is one of the most promising areas for the pharmacist to pursue as a health care professional. The traditional system , by which only certain health professionals, namely physicians, are authorized to initiate or prescribe, is criticized for contributing to the growing rate of healthcare costs and medication errors°. The processes of drug prescribing, dispensing, administering, monitoring, and adjusting doses whenever necessary, as practiced in the traditional system, occur in a separate fashion that frequently results in otherwise avoidable drugrelated problems that contribute significantly to poor patient outcomes and increased medical costs2). Ernst and colleagues showed that drug-related problems in the United States exceeds $177 billion dollars annually and is the cause of numerous unnecessary hospitalizations and deaths each year3) .
In nursing homes, medication-related errors or adverse reactions cost $ 1.33 for every $ 1 spent on the medications4). Although medication error rates are not routinely tracked among many institutions in Japan, data from a medication error reporting program at a university hospital detected nearly two medication errors per day which were voluntarily reported by hospital staff or patients within a 2-year periods) .
Shimp and colleagues found that the strongest predictor of potential drug-related problems is the number of prescription medications a patient is receiving6). In order to minimize the frequency of avoidable drug-induced problems and enhance patients' health-related quality of life, an interdisciplinary approach to patient care through collaborative drug therapy management is emerging1).
History
Throughout history, pharmacists had always been allowed to "prescribe," or recommend medications for patients who came into the pharmacy. Frequently, pharmacists prepared their own "concoctions" or remedies for patients with their own secret formulas7). However, in 1938, the United States enacted the Federal Food, Drug, and Cosmetic (FDC) Act to protect the safety of patients against misbranded prescriptions that were inadequately labeled with instructions for use or possible adverse effects that may occur with use's. In 1951, the Durham-Humphrey Amendment resulted in the legal separation of prescribing by physicians and dispensing of drugs by pharmacists8). It was thought that these restrictions were in the best interest of patients and the health care system, particularly in regard to safety. However, with the dramatic increase in the number of complex medications developed by pharmaceutical manufacturers since the "golden age of drug discovery" following World War II, it has become difficult for physicians to keep abreast of technological advances in both the medical and pharmaceutical fields9). While only 650 medications were available for use in the 1960' s, more than 10,000 different medications on the market within the United States today (Pharmacists for Quality Patient Care, Alliance for Pharmaceutical Care, Partners to Improve Health Outcomes URL http : //www.accp.com/position/paper 11.pdf (accessed 2004 Nov 4)). Since reports on medication errors and drug-related morbidity and mortality have also received increased attention in the medical literature in recent years, many have called into question this complete separation of prescribing and dispensing10, 11).
Current
Status of Healthcare
The economic and social influences on health care have driven the mission towards a new approach to pharmacists' roles in the care of patients. In the United States, the "baby boomer" population will reach retirement age around the year 201012). This dramatic increase in the age of the population, many of whom are receiving multiple medications for various chronic medical conditions, is driving healthcare expenditures upward at a rapid pace. In an effort to control costs of hospitalization, Medicare and many other private insurance companies have implemented prospective "diagnosisrelated-group" or DRG prospective payment systems. Hospitals receive a fixed reimbursement for the primary diagnosis a patient has during hospital admission, even if the hospital spends more or less money treating the patient12). In Japan, a similar rise in the elderly population has boosted medical expenditures at an alarming rate. Under proposed reforms within the national health insurance system, a similar diagnosis-related group payment system is undergoing pilot testing to eliminate the expensive fee-for-service system that currently exists13, 14) .
In both the United States and Japan, society is undergoing an "information revolution." With electronic transmission of prescriptions to pharmacies and the computerization of hospital medical records, more pharmacists are privy to patient information that was not previously available before the technology age12, 15).
Due to the philosophical changes in pharmaceutical education which have taken place in the past 25 years in the United States16), the field of pharmacy has undergone a "reprofessionalization"12). It was in 1973 that the Indian Health Service (IHS) piloted the Pharmacist Practitioner Training Program (PPTP), whereby pharmacists could provide collaborative drug therapy management for patients following completion of an intensive training program supervised by physicians17,18). It was found in an assessment of this program that the quality of care provided by pharmacists, as judged by auditors, was similar to physician-provided care. Questionnaires rating physician and patient satisfaction with the program indicated that both groups had favorable opinions of the PPTP and the care that pharmacists provided18).
In 1987, the American Association of Colleges of Pharmacy (AACP) approved a mandatory 6-year doctor of pharmacy degree program with heightened emphasis on providing pharmaceutical care to patients19). By embracing pharmaceutical care, pharmacists can focus on optimizing patients' medication regimens and preventing adverse drug reactions and drug-drug interactions, instead of simply providing a prescription or over-the-counter medication to a patient with some patient education materials20). Optimal drug therapy outcomes are achieved through selecting rational, costeffective drug therapy and preventive identification and correction of adverse drug reactions and drug-related problems, including supra-or subtherapeutic doses of medications, untreated indications, unnecessary medications, duplicate drug therapy, inappropriate drug or dose of therapy, or the need for pharmacokinetic therapeutic drug monitoring (TDM) to attain an adequate dose of medication for the patient to achieve the desired response20, 21).
Evidence of Impact of Pharmacists on Patient's Health
In recent years, the development, promotion, and publication of pharmacists' clinical activities in managing patients within the United States has driven support for the continued expansion of collaborative roles in caring for patients. Since the early papers detailing the success of clinical pharmacy services were published in the 1970' s, numerous peerreviewed publications in the medical literature have documented the positive impact of pharmacists' new clinical roles on economic and therapeutic outcomes22). These publications have caught the attention of the public eye, and the United States government, as it seeks new ways to reduce the costs associated with the growing elderly population. The most profound evidence showing the impact of pharmacists on patient care is from pharmacists practicing collaboratively with physicians in the hospital setting. Bond and colleagues have shown a 65 % reduction in medication errors in hospitals with a high number of clinical pharmacists providing pharmaceutical care to patients compared to those hospitals with minimal or no clinical pharmacy staff. Lower rates of medication errors were also correlated with pharmacist-provided adverse drug reaction management, drug protocol management, drug information services, and admission histories23). Pharmacists attending rounds with physicians in the intensive care units similarly decreased the rate of adverse drug events by 66% and nearly 90% of the 400 interventions made over a 6-month period of time were to correct or prevent potential medication errors. The cost avoidance estimates of this clinical pharmacy service provided annually is nearly $ 270,000 in savings24).
Definition of Collaborative Drug Therapy Management
Collaborative drug therapy management (CDTM) can exist between one or more physicians and pharmacists in the hospital or community setting. Collaborating pharmacists and physicians work together to develop a written drug therapy management protocol, or agreement for the scope of patient management activities a pharmacist is permitted to perform in order to improve patient care outcomes18). Many protocols incorporate evidence-based clinical practice guidelines or goals for disease state outcomes developed by national agencies in order to guide pharmacists' decisionmaking processes (American Society of Consultant Pharmacists, ASCP Policy Statement, Statement on collaborative practice, URL http : //www.ascp.com/public/pr/policy/collaborative.shtml (accessed 7 Oct 2004)). Under such a protocol, a qualified pharmacist is granted legal authority to provide services such as physical or health assessments, ordering medication-related laboratory tests, administering certain drugs, or selecting, initiating, monitoring, continuing, and modifying medication regimens18). (American Society of Consultant Pharmacists, ASCP Policy Statement, Statement on Collaborative Practice, URL http : //www.ascp.com/public/pr/policy/collaborative.shtml (accessed 7 Oct 2004)). Documentation of the protocol agreement and pharmacist's recommendations are placed in the patient' s permanent medical record to allow other health care professionals caring for the patient to see the pharmacist' s interactions with the patient and plans for the drug therapy regimen18).
Legal Considerations
Involved with CDTM In July 2004, 11 national pharmacy organizations uniformly agreed to a scope of practice for pharmacists to provide "Medication Therapy Management Services" for Medicare patients. Under this defined scope of practice, pharmacists would be able to obtain records of or perform a patient's health assessment, develop a medication treatment regimen to treat the patient's diagnosed disease states by either selecting new medications or altering the patient' s current medication regimen, monitoring the efficacy and safety of medications prescribed for each patient, evaluating the patient for potential drug-drug interactions or adverse drug reactions, and administering medications in specific situations. Pharmacists would also be able to educate patients about their medications and coordinate their medication therapy plan with other health services the patient is receiving. For the first time in the United States, pharmacists would receive governmental payment for clinical services provided to all of the patients they manage who are insured through governmental healthcare. Patients specifically targeted by this plan include those that are receiving at least four prescriptions, spending over $ 250 in medications per month or over $ 650 in medications per quarter, and patients who are seeing multiple physicians.
Requirements for Collaborative Drug Therapy Management
It is important to note that several requirements must be met in order for pharmacists to participate productively in collaborative drug therapy management. These considerations include an environment suitable for collaborative practice, access to patients and their medical records, competent pharmacists with specialized knowledge, skills, and abilities in the given disease area, written documentation of pharmacist' s activities, and monetary compensation for services performed1,18).
Collaborative practice environment
Pharmacists need to identify a physician or provider group, that is willing to collaborate with a pharmacist. The physician or health system will then identify patient populations, disease states, specific drugs, and certain drug-related issues in which health professionals wish to manage collaboratively with pharmacists25). Zillich and colleagues found that the most influential factors in developing a collaborative relationship between pharmacist and physician are role specification, trustworthiness, and relationship initiation27). Pharmacists must work with physicians to establish which roles the pharmacist and physician will take in sharing the responsibility for patient care. Outlining the professional duties and general areas of responsibility will become the approved scope of practice for that pharmacist18). Pharmacists should be visible to physicians and provide more than what is expected when a physician asks for information from the pharmacist. If the physicians continuously receive more than they expect to receive from pharmacists, it makes a good impression, and an atmosphere of trust is established. Additionally, pharmacists must be present in the clinics for a consistent amount of time each day or week, so the physicians can ensure the pharmacists are reliable, dedicated members of the healthcare team25).
Access to patients and medical records
Accomplishing collaborative drug therapy management relies on developing a trustworthy relationship not only with physicians, but also with patients. Pharmacists should clearly communicate their role in caring for patients to them. It is also imperative to gain shared access to patient' s medical records either electronically or through another mechanism so that pharmacist' s recommendations and implemented 
Documentation of activities and quality assessment
It is essential that pharmacists participating in CDTM document all clinical pharmacy activities in the patient' s medical chart. Additionally, in order to demonstrate the quality and value of services provided, to win the trust of physician and patient collaborators, and to be able to expand the scope of pharmacist practice in the future, it is essential that pharmacists track the clinical outcomes achieved with patients that are managed closely by the pharmacist under CDTM18, 25). In a publication by Rupp et al., community pharmacists who managed asthma patients decreased hospital admissions by 77 % and emergency department visits by 78%30). Munroe and colleagues showed that pharmacists who provided disease state management services in their community pharmacies saved an average of $ 2700 per patient annually in medical costs31). Pharmacists who managed high-risk patients receiving numerous medications under collaborative practice were able to decrease the number of medications received and to save nearly $ 600 per patient annually in drug therapy costs32). Pharmacist participation in collaborative practice agreements under the Mississippi Medicaid disease management program were responsible for decreased visits to the emergency department in asthmatic patients and a significant lowering of mean hemoglobin Alc values in diabetic patients managed33).
Payment for services
Any type of practitioner must be able to generate revenue sufficient to support the direct and indirect costs of their practice activities, including CDTM. While certain CDTM protocols do establish payment of physicians for their time in reviewing pharmacists' pharmaceutical care activities, there is not a uniform system to compensate physicians under CDTM with pharmacists in the United States19). Additionally, with the exception of certain model demonstration programs, to date , pharmacists in the United States cannot yet routinely receive reimbursement from the government for care of Medicare or Medicaid patients or patients covered by third party health insurance programs, which, in total, make up 76% of patients receiving medical care in the United States34). Therefore, many pharmacists are reliant on patients to pay out-of-pocket for their drug management services. Although prices for different services vary, most pharmacists receive between $ 20 to $ 40 per patient for screening and other health management services33, 35).
Organization and systematic approach
Kuo and colleagues recommend a 10-step approach to establishing a collaborative drug therapy management practice with physicians based on their own experiences in a family medicine clinic26), and we modified the list (Table 1) . Developing a solid working relationship with physician colleagues and an environment in which pharmacists can be relied upon to provide care is the first step in creating a collaborative medication therapy management program. Global screening initiatives to identify patients at high risk for drug therapyrelated problems or adverse drug reactions can also prove successful in developing a role for pharmaceutical care. Next, pharmacists and physicians must work together to create evidence-based protocols, guidelines, and services to be performed by pharmacists25). These protocols should be approved by the appropriate legal authorities for ensuring patient safety, possibly including licensing boards or governmental agencies. Pharmacists must receive permission by their employers and possibly undergo a credentialing process to ensure they are qualified to perform the duties outlined within the collaborative practice protocol. Information required for billing records should be sought in advance of seeing patients, so that pharmacists can include these specific details within medical chart progress notes in order to receive reimbursement promptly. Pharmacists should design a template for writing medical progress notes in patients' charts so that they can be consistent and efficient in documenting patient interactions and recommendations for medication changes. A budget should be developed to determine start-up expenses required for purchasing point-of-care or other patient monitoring and physical assessment equipment, reference books, computers, or for reorganizing workspace in order to see patients. Finally, pharmacists should document the outcomes of all interventions made on patients seen through collaborative practice agreements so that the quality of care can be evaluated26).
Status of Collaborative
Drug Therapy Management in the United States in 2004
As of January 2004, 40 states in the United States have established statutes or regulations for CDTM by pharmacists and 3 states have pending CDTM legislation. Table 2 shows CDTM authorization by state as of March 200426). Table 3 summarizes the advantages and disadvantages to initiating and maintaining a successful CDTM practice36). While clinical pharmacists in the United States have been successful in gaining physician approval to provide cognitive services, until recently, they have been largely unsuccessful in being awarded payments for these activities by governmental agencies or insurance companies. Many pharmacies rely on retail sales of non-prescription items or the nominal dispensing fees charged when prescriptions are filled to finance such efforts by pharmacists. In addition, many pharmacies charge the patients a fee for these services, and they have a fee structure equivalent to the technical difficulty of the service provided. In some practices, a billing system has been established. Billing for pharmacist-physician collaborative drug therapy management services requires the use of the physician' s unique provider identification number and CPT (current procedural terminology) evaluation and management code. Table 4 shows CPT codes and its billing requirements based on the level of service provided, and Table 5 shows an example of CDTM protocol for hyperlipidemia.
The Prescription Drug and Medicare Modernization Act of 2003 was passed in Congress and now the government is working on the operational details in time for a January 2006 start date. One of the essential aspects of this bill was the definition of pharmacist provider activities which can be billed for under a collaborative practice agreement with another healthcare provider (Table 6 ).
Japan Perspective
Japan has decided to launch a 6-year pharmacy education system beginning in the year 2006. This means that medical schools and pharmacy schools now have the same duration of professional training in schools. With the added clinical therapeutics focus in the two-year curriculum addition, phar- With regard to the practical steps for launching CDTM, it is logical for the CDTM to be initiated by the prefecture or locally. The prefecture or local group of pharmacists must make a positive impact on physicians by demonstrating the competency of the pharmacists' drug therapy knowledge. Pharmacists practicing within a university setting are another source for program development. Clinical faculty members, whose number will increase as 6-year programs launch in 2006, should take the initiative to establish CDTM as part of their clinical practice. Professional pharmaceutical societies and licensure authorities can play a key role in developing sample drug therapy management protocols that could easily be manipulated for a given clinic or hospital scenario (Louisiana State Board of Nursing, Sample collaborative practice agreement, URL http : //www.lsbn.state.la.us/documents/ Forms/collab.pdf (accessed 20 Oct 2004)).
Once CDTM is established between a pharmacist and physician, the next step is for CDTM to be recognized within the health insurance system so that the pharmacists can be reimbursed for the CDTM services they provide. It will become possible for the CDTM to be included in the national health insurance system once pharmacist' s involvement in CDTM proves to be beneficial for patients and economical for the health care system as a whole. Subsequently, pharmacists can market the cost-effective and safe services they provide to the healthcare system. In addition to utilizing a step by step approach for launching CDTM, it is important for pharmacists to demonstrate competence in professional knowledge and superb interpersonal communication skills when interacting with physicians, patients, and administrators. By communicating effectively, both patients and physicians will easily see the benefits a pharmacist can provide to patients under a CDTM arrangement.
Conclusion
Collaborative drug therapy management is a positive approach to guide the profession of pharmacy into a more patient-oriented focus. Many pharmacists in the United pharmacists can provide with the training received under 6-year clinical pharmacy programs. If pharmacists in Japan are able to remove these potential barriers to true pharmaceutical care, they will enjoy an enhanced professional status and some of the most advanced pharmacy-initiated patient care practices in the world. 
